Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 3/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.53 |
| ▸ | CLK2 | P49760 | 2/20 | 0.53 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | MELK | Q14680 | 2/20 | 0.53 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.53 |
| ▸ | FECH | P22830 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502938 | 0.85 | GAK (0.49) | CSNK1DPRKD3MAP4K4MAPK9CLK2 | |
| SCHEMBL10022419 | 0.84 | IDO1 (0.58) | ENPP2IDO1 | |
| SCHEMBL5382298 | 0.84 | GAK (0.56) | CSNK1DPRKD3MAP4K4MAPK9CLK2 | |
| SCHEMBL8365703 | 0.82 | MKNK1 (0.60) | CSNK1DPRKD3MAP4K4MAPK9CLK2 | |
| SCHEMBL5372315 | 0.81 | IDO1 (0.69) | CSNK1DPRKD3MAP4K4MAPK9CLK2 | |
| SCHEMBL8257010 | 0.81 | ENPP2 (0.69) | CSNK1DPRKD3MAP4K4MAPK9CLK2 | |
| SCHEMBL5372940 | 0.80 | MAPK9 (0.54) | CSNK1DPRKD3MAP4K4MAPK9CLK2 | |
| SCHEMBL8257804 | 0.80 | MAP3K5 (0.45) | MAP4K4CLK4GSK3BMAP3K5MKNK1 | |
| SCHEMBL5373153 | 0.80 | MAP3K5 (0.47) | CSNK1DPRKD3MAP4K4MAPK9CLK2 | |
| SCHEMBL5380111 | 0.80 | MAP3K5 (0.47) | CSNK1DPRKD3MAP4K4MAPK9CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-6838583-B2 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and the methods of using the same | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-04 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | CSNK1D 349/4885PRKD3 135/4885MAP4K4 65/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CSNK1D 164/4885PRKD3 70/4885MAP4K4 41/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CSNK1D 245/4885PRKD3 79/4885MAP4K4 38/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CSNK1D 164/4885PRKD3 70/4885MAP4K4 41/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | CSNK1D 410/4885PRKD3 152/4885MAP4K4 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.